Sofosbuvir treatment and hepatitis C virus infection

doi:10.4254/wjh.v8.i3.183

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 8, Issue 3

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (8774)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-4) series.

Item

Count

PDF

558

WORD

206

HTML

3804

Tables (1-4)

232

Sum=4800

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

454

Download

773

Sum=1227

Publishing Process of This Article

Item

Count

Browse

1130

Download

1617

Sum=2747

Jan 28, 2016 (publication date) through Nov 29, 2024

Times Cited of This Article

Times Cited (14)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Hepatol. Jan 28, 2016; 8(3): 183-190
Published online Jan 28, 2016. doi: 10.4254/wjh.v8.i3.183

Table 2 Summary of phase 3 study for hepatitis C virus genotype 2-infected patients

Study name	Population	Treatment	Duration (wk)	n	LC (%)	SVR12 (%)
						All	Non-LC	LC
FISSION	Naïve	SOF/RBV	12	70	-	97	-	-
POSITRON	IFN-ineligible/intolerant	SOF/RBV	12	109	15	93	92	94
VALENCE	Naïve	SOF/RBV	12	32	-	97	97	100
Japanese study	Naïve	SOF/RBV	12	90	9	98	97	100
FUSION	Experienced	SOF/RBV	12	36	28	86	96	60
			16	32	-	94	100	78
VALENCE	Experienced	SOF/RBV	12	41	-	90	91	88
Japanese study	Experienced	SOF/RBV	12	63	14	95	96	89

LC: Liver cirrhosis; SVR12: Sustained virologic response at 12 wk; Naïve: Treatment-naïve; Experienced: Treatment-experienced; SOF: Sofosbuvir; IFN: Interferon; RBV: Ribavirin.

Citation: Nakamura M, Kanda T, Haga Y, Sasaki R, Wu S, Nakamoto S, Yasui S, Arai M, Imazeki F, Yokosuka O. Sofosbuvir treatment and hepatitis C virus infection. World J Hepatol 2016; 8(3): 183-190
URL: https://www.wjgnet.com/1948-5182/full/v8/i3/183.htm
DOI: https://dx.doi.org/10.4254/wjh.v8.i3.183